BioClinica ®, Inc. (NASDAQ: BIOC), a global provider of clinical trial management solutions, today announced an agreement for BioClinica Express EDC, data management, and imaging core lab services with Finnish company Medtentia International, in partnership with the contract research organization (CRO) clinicalprojects international (CPI). Medtentia International Ltd. is a medical technology company which develops solutions for mitral valve repair based on its proprietary helix ring concept. Medtentia’s technology has the potential to reduce the invasiveness, operation time and morbidity associated with mitral valve repair operations.
Medtentia is the latest European customer to select BioClinica eClinical and Imaging Core Lab offerings. BioClinica services will support Medtentia’s multi-country, multi-year study of a medical device for mitral valve (heart) repair. "We awarded this clinical trial to CPI and BioClinica based on the excellent feedback we received from their reference clients,” commented Olli Keranen, CEO of Medtentia. “We were already familiar with BioClinica’s Imaging Core Lab solutions and wanted to outsource EDC and DM to a stable global eClinical vendor. We are confident that both companies’ reputations for customer focus and respective strengths will well serve the needs of an innovative medical device company like Medtentia."
Based in Bonn, Germany, CPI is focused on the planning and execution of Phase I-IV as well as post-marketing studies for innovative medical devices, combination products and (Bio)Pharmaceuticals. “We are delighted that Medtentia has entrusted us with their trial and look forward to another successful collaboration with the BioClinica team,” said Jörg Breitkopf, Managing Director of CPI. “BioClinica has a strong service and technology reputation among medical device companies. Our partnership will provide Medtentia with the utmost in clinical trial support.”
"BioClinica’s fresh and more cost-efficient approach to clinical trial support is currently driving unprecedented sponsor and CRO partnership growth across both eClinical and Imaging Core Labs solutions,” said Mark Weinstein, CEO of BioClinica. We continue to expand our team, especially in Europe, adding to our experience and global reach, and are pleased to have been selected to help support this important cardiac device research.”
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts